Brain Tumor Center
The Jefferson Brain Tumor Center of the Sidney Kimmel Cancer Center provides a multidisciplinary approach to treating brain tumors, giving patients access to care all in one place and during one visit. Combining expertise in Radiation Oncology, Neurosurgery and Medical Oncology, our Center physicians provide exceptional care and access to the latest protocols for patients coping with this life-threatening diagnosis.
Advantages of Choosing Jefferson for Brain Tumor Treatment
Our Brain Tumor Center distinguishes itself in many ways:
- The volume of patients we have treated (more than 3,000)
- Our team of experts performs more than 600 surgeries annually, making Jefferson one of the busiest brain tumor practices in the tri-state area.
- Our surgical approaches and radiosurgery techniques yield an overall volume that is unrivaled in the tri-state area.
- We have the largest number of neurosurgeons, neuro-oncologists and radiation oncologists dedicated to treating brain tumors of any center within a 100-mile radius.
The Sidney Kimmel Cancer Center at Jefferson, a National Cancer Institute (NCI)-designated clinical cancer center, treats more patients with malignant and benign brain tumors than all other area university-based hospital programs combined. Our specialists create a seamless and carefully coordinated treatment plan for a patient in just a few minutes. This is important because a delay in treatment diminishes success for patients.
Multidisciplinary Brain Tumor Board
This multispecialty group has been continuously convening every week since 1994 to discuss the management and treatment of challenging brain tumor cases. Attended by neurosurgeons, radiation oncologists, neuro-oncologists, neuroradiologists, residents, fellows, nurse practitioners and nurses, this group has overseen the successful and innovative treatment of more than 3,000 brain tumor patients in the course of its operation.
Our team of neuro-oncologists coordinate comprehensive and leading-edge treatment for our patients. We systematically review each case at our weekly multidisciplinary Brain Tumor Board and actively engage our patients in a number of ongoing institutional and national clinical trials.
Stereotactic Radiosurgery Treatment
Our team has 20+ years of experience treating more than 5,000 benign and malignant brain tumors. We are pioneers in the development of fractionated stereotactic radiotherapy with the first installation worldwide of a LINAC designed for and dedicated to radiosurgery.
Using leading-edge noninvasive techniques, our radiosurgery platforms allow us to treat a number of brain tumors, skull base tumors and facial pain by creating a complex sculpted radiation plan tailored to the individual patient's tumor.
Brain Tumor Clinical Trials and Research
At the Jefferson Brain Tumor Center, we offer numerous leading-edge clinical trials for our patients and are involved in ongoing brain tumor research.
There are approximately 17,000 primary brain tumors diagnosed in the United States each year, 60 percent of which are gliomas. Minimizing neurological side effects in patients with high-grade gliomas from chemoradiation may result in improved patient survival, a new study from our radiation oncologists suggests.
It is generally considered that the only way to improve survival in malignant brain tumors is to more effectively attack the tumor. However, our research suggests that damage to surrounding normal tissue may also play a role in determining a patient's long-term outcome.
Other researchers from Jefferson have found that patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives.
Not only does hypofractionated stereotactic radiotherapy provide longer survival, patients do not experience side effects commonly seen with use of chemotherapies and targeted therapies. These findings set a new bar for the treatment of recurrent gliomas.
Make an Appointment
Call 1-800-JEFF-NOW (1-800-533-3669) to make an appointment with a Jefferson Health specialist at our Brain Tumor Center.